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Background/aim: Abnormalities in oral mucosal immunity contribute to complex pathogenesis of primary Sjögren’s syndrome (pSjS).
We aimed to measure saliva and serum levels of caspase-1, tumor necrosis factor-alpha (TNF-α) and interferon gamma (IFN-γ) in
patients with pSjS.
Materials and methods: We studied 43 pSjS patients fulfilling the AECG criteria and 30 age/sex-matched healthy controls, as well
as 39 rheumatoid arthritis (RA) patients as a disease control group. ESSDAI scores were less than seven in all patients with pSjS,
indicating low disease activity. Quantitative analyses were made in serum and whole saliva samples. The statistical analysis was
performed using SPSS 19.0.
Results: While no significant difference was found in serum measurements, saliva levels of TNF-α and caspase-1 were significantly
higher in pSjS patients versus healthy controls when using the Mann–Whitney U test. On the other hand, in the pSjS group, saliva
levels of TNF-α and caspase-1 were also significantly higher compared to the RA group using Student’s t-test. In the pSjS group, those
parameters did not show any correlation with disease duration, seropositivity, and smoking.
Conclusion: Despite low disease activity, saliva TNF-α and caspase-1 levels were found to be significantly higher in the pSjS group,
which may suggest a possible advantage of local anticytokine treatments in selected cases.
Key words: Primary Sjögren’s syndrome, caspase-1, tumor necrosis factor-alpha, interferon gamma, local treatment

1. Introduction
Sjögren’s syndrome (SjS) is a chronic inflammatory
autoimmune disease of unknown etiology, characterized
by lymphocytic infiltration of exocrine glands resulting in
dryness of the eyes and mouth. Extraglandular involvements
such as arthritis, vasculitis, and hematological, pulmonary,
and renal diseases may also occur. This disease is classified
as ‘primary’ (pSjS) when it occurs by itself and ‘secondary’
when it occurs with another autoimmune disease (1,2).
Despite extensive investigations, the disease-initiating
events in the target exocrine glands are not known (1,2).
Rheumatoid arthritis (RA) manifests clinically as
symmetric inflammation of the small joints in the hands
and feet particularly. Chronic synovial inflammation leads
to progressive destruction of joint cartilage and underlying
bone (3).
* Correspondence: gonca4us@yahoo.com
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Cytokines are small soluble peptides. They are used by
the immune system to communicate and influence cellular
function. Cytokines are released mostly by immune cells.
Their functions can be autocrine, paracrine, or endocrine
(4). Cytokines are regulators of the innate and adaptive
immune system. They control the direction, amplitude,
and duration of the inflammatory response (5).
Traditionally, the dominant role of the adaptive immune
system in the pathogenesis of pSjS has been attributed
mainly to the presence of lymphocytic infiltrates in the
glands, and to the positivity of specific autoantibodies
such as anti-Ro/SSA and anti-La/SSB. The exact cause
of exocrine dysfunction in pSjS remains unclear. It has
recently been suggested that not only the adaptive immune
system but also the innate immune system may contribute
significantly to the glandular damage (6). Since the
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salivary glands are the main target organs in pSjS, saliva
may be better than serum as an ideal biological fluid to be
investigated that closely reflects the underlying pathology
of autoimmune glandular exocrinopathy in pSjS (7). In
line with this assumption, increased saliva levels of various
cytokines, including interleukin 1 beta (IL-1β), tumor
necrosis factor-alpha (TNF-α), and interferon gamma
(IFN-γ), had already been shown in previous studies,
reflecting the possible contribution of these cytokines in
oral mucosal pathogenesis in pSjS. However, data regarding
salivary levels of caspase-1, which is a very important
enzyme contributing to local mucosal innate immunity, are
limited. Therefore, we intended to investigate salivary levels
of caspase-1, in addition to two prominent inflammatory
cytokines, namely IFN-γ and TNF-α. Although because
of technical problems we could not include IL-1, we
believe that the triple combination of caspase-1, IFN-γ,
and TNF-α may reflect the contribution of innate and
adaptive immunity in local mucosal pathogenesis in pSjS.
The present study was thus conducted to determine both
saliva and serum levels of caspase-1, TNF-α, and IFN-γ
in patients with pSjS, compared to both healthy controls
and to patients with RA as a disease control group. We
also aimed to investigate whether there is any correlation
between the levels of these cytokines/enzymes and various
clinical/laboratory parameters of pSjS.
2. Materials and methods
2.1. Patients and controls
This cross-sectional study was conducted by the enrollment
of 43 patients with pSjS (F/M: 40/3, mean age ± SD: 51.1
± 14.5 years, mean disease duration: 10.7 ± 7.1 years), all
fulfilling the United States-European Consensus Criteria
(8), and 30 healthy controls age- and sex-matched with the
pSjS group. All of the healthy controls were recruited from
the staff of Ege University Hospital and special attention
was paid to exclude the relatives of the patients as healthy
controls. While serum samples were obtained from all of
the healthy controls, unfortunately saliva samples could
not be obtained from 3 healthy controls. Besides, 39
patients with RA (F/M: 29/10, mean age ± SD: 54.6 ± 12.9
years, mean disease duration: 10.8 ± 6.0 years) all fulfilling
the 2010 American College of Rheumatology/European
League Against Rheumatism (ACR/EULAR) criteria were
also included as the disease control group (9).
The study patients were followed up at the Outpatient
Clinic of the Department of Rheumatology at Ege
University Hospital. All the medical records of the patients
were carefully noted and a physical examination was
performed for each patient. Exclusion criteria included
the following: 1) pregnancy; 2) presence of any other
known systemic diseases; 3) recent usage of antibiotics; 4)
presence of periodontitis; 5) being edentulous.

None of the study participants, including both study
groups and healthy controls, had oral mucosal lesions or
dental problems.
None of the RA patients had clinical or laboratory
features suggesting the presence of secondary SjS.
Among our patents with pSjS, 24/43 had extraglandular
involvement, and the distribution of extraglandular
involvements is given in Table 1. All of the pSjS patients had
been under usual corticosteroid and immunosuppressive
treatment, and medications were not changed or stopped
before enrollment in the study. Disease activity was
determined according to the standard disease activity
index, defined by EULAR, known as the Sjögren’s
Syndrome Disease Activity Index (ESSDAI) (10). ESSDAI
scores of 0–7 were defined as mild disease, whereas scores
above seven were defined as active disease. Disease activity
in RA patients was determined on the basis of a disease
activity score known as DAS 28 (11). RA patients having
DAS 28 scores of 3.2 or higher were accepted to have active
disease. Smoking status was determined according to selfreports of the study subjects.
2.2. Laboratory analysis
2.2.1. Serum sampling
Five milliliters of venous blood were taken from the
antecubital vein by a standard venipuncture method, and
serum was separated from blood by centrifugation at 1500
× g for 10 min. The serum samples were then stored at
–40 °C until subsequent biochemical analyses and thawed
immediately before assay.
2.2.2 Saliva sampling
Whole saliva samples were obtained from all patients and
27 out of thirty healthy controls, simply by expectorating
into polypropylene tubes before clinical periodontal
measurements or any periodontal intervention, in the
morning time after an overnight fasting. The participants
were requested not to drink (except water) or chew
gum during sample collection. The samples were then
frozen immediately and stored at –40 °C until the sample
collection period was completed and thawed immediately
before assays.
Antinuclear autoantibodies (ANAs) were determined
and quantified using indirect immunofluorescence
technology (Hep2 cells; Diamedix, Miami, FL, USA).
Titers of 1/80 or higher were considered as positive. AntiRo/SSA and anti-La/SSB autoantibodies were detected
by an enzyme-linked immunosorbent assay (ELISA) for
the quantitative determination of IgG autoantibodies
(ORGENTEC Diagnostica, Mainz, Germany). The cut-off
value was 15 U/mL, as recommended by the manufacturer.
Quantitative determination of serum rheumatoid factor
(RF) was performed using an immunonephelometry test
(Siemens, Marburg, Germany). RF was considered to be
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Table 1. Clinical and laboratory features of the patients with pSjS.
Sex

N

%

Female/Male

40/3

93.0/7.0

Dry mouth

41

97.6

Dry eyes

39

92.9

Extraglandular manifestations

24

55.8

Raynaud phenomenon

9

20.9

Arthritis

13

30.2

Cutaneous manifestations

4

9.3

Pulmonary involvement

7

16.3

Hematological involvement

4

8.9

Liver involvement

8

18.6

Renal involvement

1

2.3

Neurological involvement

1

2.3

Vasculitis

2

4.7

Myositis

2

4.7

25

58.1

Antinuclear antibody positivity

35

72.9

Anti Ro/SS-A positivity

30

71.43

Anti La/SS-B positivity

16

38.15

Rheumatoid factor positivity

17

36.2

Cryoglobulin positivity

1

2.6

Serum complement 3

4

10.5

Serum complement 4

1

2.6

Chisholm I

1

2.5

Chisholm II

1

2.5

Chisholm III

14

35.0

Chisholm IV

24

60.0

Current smokers

5

11.6

Nonsmokers

31

72.1

Former smokers

7

16.3

Subjective symptoms

Eye findings
Positive Schirmer’s I test
Immunological features

Low complement levels

Minor salivary gland biopsy *

Cigarette smoking

*Minor salivary gland biopsy was available for 40 out of 43
patients with pSjS.
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positive when the concentration was higher than the cutoff value of the kit (15.9 IU/mL).
Specific ELISA kits for TNF-α and IFN-γ (eBioscience,
San Diego, CA, USA) and caspase-1 (Sunredbio,
Shanghai, China) were used for quantitative analyses. The
assays were performed according to the manufacturer’s
recommendations. The minimum detection limits were
2.3 pg/mL, 0.99 pg/mL, and 0.117 ng/mL for TNF-α,
IFN-γ, and caspase-1, respectively. Fifty (TNF-α, IFN-γ)
or forty (caspase-1) microliter aliquots of saliva or serum
were used for all assays and each assay was performed in
duplicate.
Objective evaluation of ocular involvement was
considered on the basis of a positive result for Schirmer’s I
test (without anesthesia; ≤5 mm/5 min).
This study was performed according to the principles
of the Declaration of Helsinki and was approved by the
local ethics committee; written informed consent was
obtained from all the participants.
2.3 Statistical analysis
The statistical analysis was performed using SPSS 19.0.
The Mann–Whitney U or Kruskal–Wallis test was used for
the parameters that did not show a normal distribution.
Student’s t-test was used for the parameters that showed a
normal distribution. P < 0.05 was accepted as statistically
significant.
3. Results
Clinical and laboratory features of the patients with pSjS
are shown in Table 1. As shown in detail in Table 1, at
least one extraglandular involvement was present in 24/43
(55.8%) of the patients with pSjS. Among patients with
pSjS, there were no cases having an ESSDAI score of higher
than seven. In other words, all of the patients with pSjS,
including those with extraglandular involvement, had low
disease activity. During enrollment in the study, treatment
agents that the patients had been receiving included
corticosteroids (n: 7; 16.3%), hydroxychloroquine (n: 24;
60.0%), methotrexate (n: 5; 11.6%), azathioprine (n: 4,
9.3%), and leflunomide (n: 1; 2.3%). None of the patients
had received any biologic treatment. The frequency of
RA patients having DAS 28 score higher than 3.2 was
26.3% (n: 10). Rheumatoid factor positivity was present in
76.9% (n: 30), anti-CCP positivity in 66.7% (n: 24), and
ANA positivity in 34.2% (n: 13). The frequency of current
smokers among RA patients was 18.4%, nonsmokers
68.4% (n: 26), and former smokers 13.2% (n: 5).
Serum levels of caspase-1, TNF-α, and IFN-γ were not
significantly different between the pSjS and RA groups
and healthy controls. However, there were significant
differences in saliva measurements. When we compared
the saliva levels of caspase-1, TNF-α, and IFN-γ between
the three groups, using the Kruskal–Wallis test, we found
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and compared them to both healthy controls and the RA
group. Although there was no significant difference in
serum measurements between the three groups, saliva
levels of TNF-α and caspase-1 in the pSjS group were
significantly higher than in both healthy controls and the
RA group. However, saliva levels of these parameters in
the pSjS group did not show any correlation with disease
duration, ANA or RF positivity, or smoking. The patients
included in the pSjS group were notable for having low
disease activity.
Elevated saliva levels of TNF-α and caspase-1 found
in the present study may support the well-known role of
innate immunity in mucosal inflammation of pSjS, and
might contribute to pathogenesis of pSjS by inducing
apoptosis of epithelial cells in the oral and ocular mucosa
(12). Elevated TNF-α saliva levels in pSjS were also
reported in the literature (13,14). Kang et al. reported
increased levels of saliva TNF-α in patients with pSjS
compared to patients having only sicca symptoms (13).
On the other hand, Zhou et al. addressed the importance
of locally produced TNF-α in an experimental model,
using NOD mice. They demonstrated that neutralization
of TNF-α prior to disease onset impeded the onset and
development of Sjögren-like salivary gland inflammation,
as well as secretory function (15).
The data of significantly increased saliva levels of
caspase-1 in pSjS are also in line with the literature.
However, there are studies investigating the expression
of the P2X7 receptor (P2X7 R)-NLRP3 inflammasome
complex in the salivary glands (6,7), rather than measuring
directly caspase-1 saliva levels in pSjS. The prominent
components of this inflammasome complex are NLRP3,
caspase-1, and IL-18, and this complex modulates the
release of IL-1β and IL-18. Baldini et al. (6) found that the
expressions of this inflammasome complex and caspase-1
were not only significantly higher in pSjS gland specimens
compared to control groups, but also correlated with

that saliva levels of caspase-1 (P = 0.005) and TNF-α (P
< 0.0001) showed significant differences, as delineated in
Table 2.
When we compared the pSjS group with healthy
controls using the Mann–Whitney U test, with respect
to saliva levels of caspase-1, TNF-α, and IFN-γ, we found
that only saliva levels of TNF-α (P < 0.0001) and caspase-1
(P = 0.031) were significantly higher in patients with pSjS.
When we compared the pSjS and RA groups using
Student’s t-test, saliva levels of TNF-α (P < 0.0001) and
caspase-1 (P = 0.0003) were also significantly higher in
the pSjS group compared to the RA group. Although saliva
IFN-γ levels were higher in the RA group compared to the
pSjS group, this did not reach statistical significance.
Patients with pSjS and RA were investigated as to
whether serum and saliva levels of IFN-γ, caspase-1,
and TNF-α showed positive correlations with various
clinical and laboratory parameters. There were no
significant correlations with disease duration in both
patient groups. Similarly, when both patient groups were
classified according to ANA or RF positivity, or smoking
habit, there were no statistically significant differences
between the serum and saliva levels of IFN-γ, caspase-1,
and TNF-α in both groups. Since all of the patients with
pSjS had low disease activity, we could not investigate a
difference between pSjS patients with and without disease
activity. In the RA group, serum and saliva levels of these
three cytokines/enzymes were not significantly different
between patients with and without active disease.
4. Discussion
In the literature, although there are studies investigating
serum and saliva levels of various cytokines, including
IL-1β, IFN-γ, and TNF-α, in patients with pSjS, studies
focusing on saliva caspase-1 levels are remarkably rare.
In the present study, we measured saliva and serum levels
of caspase-1, TNF-α, and IFN-γ in patients with pSjS

Table 2. Saliva levels of IFN-γ, caspase-1, and TNF-α in patient groups and healthy controls.
pSjS
n: 43

RA
n: 39

HC
n: 27

IFN-γ (pg/mL)
Mean (min–max) ±SD

2.9 (0.4–13.5) ±3.5

4.5 (0.5–45.4) ±7.0

3.3 (1.9–9.4) ±1.7

Caspase-1 (ng/mL)
Mean (min–max) ±SD

9.3 (2.8–16.1) ±2.3

7.7 (3.0–14.1) ±2.3

8.3 (5.4–10.9) ±1.7

TNF-α (pg/mL)
Mean (min–max) ±SD

20.8 (3.0–88.2) ±16.9

6.0 (1.8–24.0) ±5.4

4.1 (2.1–8.6) ±1.7

Saliva

Statistics
P*
0.306
0.005
0.0001

HC: Healthy controls.
*Kruskal–Wallis test.
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anti-Ro/SSA positivity and with focus score. In another
study, Baldini et al. (7) reported that salivary gland gene
expressions of P2X7R, caspase-1, and IL-18 were strongly
higher in patients with pSjS developing MALToma over
the follow-up. In the literature, potential involvement of
other inflammatory caspases in the pathogenesis of pSjS
is also reported (16). Based upon studies performed in
NOD autoimmune-prone mice, Bulosan et al. (16) showed
upregulation of caspase-11 in macrophages, supporting
the role of abnormal innate immunity in pSjS.
Given that saliva caspase-1 is found to be elevated in
the present study and in previous studies reported in the
literature, similar elevation in saliva levels of IL-1β is also
expected. Although we could not investigate saliva IL-1β
levels, increased concentrations of IL-1 in the salivary fluid
and peripheral blood of patients with pSjS were reported
by Willeke et al. (17). Furthermore, Dubost et al. (18)
suggested that the salivary IL-1/IL-Ra imbalance might
promote inflammatory lesions in the mouth. Muraki et
al. (19) reported that IL-1β is involved in the destruction
of salivary and lacrimal glands. In fact, IL-1β may have a
proteolytic activity, leading to acinar and ductal structure
disruption in the salivary glands of patients with pSjS.
In previous studies, saliva IFN-γ levels were found
to be elevated and an IFN-γ signature was found to be
present in patients with pSjS (13,14). Kang et al. (13)
reported increased levels of saliva IFN-γ, IL-1, IL6, and IL-10 levels in patients with pSjS compared to
patients having only sicca symptoms. Fox et al. (14) also
investigated saliva levels of those four cytokines in patients
with pSjS using an ELISA assay. However, they used a
different methodology; they collected saliva directly from
Stensen’s duct, i.e. the opening of the parotid gland. They
found significantly elevated levels of all these cytokines
compared to healthy controls. These investigators also
studied mRNA expression of these cytokines in salivary
gland biopsies using PCR and found higher levels (14).
The controversial finding of low saliva IFN-γ levels in
the present study may be explained by low disease activity,
as indicated by low ESSDAI scores. On the other hand,
high IFN activity is not a rule in pSjS. In a previous study,
the pattern of cytokine mRNA expression was studied in
frozen minor salivary gland tissues from patients with
pSjS. Interestingly, increased expression of IFN-γ mRNA
was detected in only three out of 12 biopsy specimens (20).
Similarly, Hall et al. (21) demonstrated high IFN activity
in only 31 out of 53 pSjS patients and reported that high
IFN activity was associated with a more severe disease
phenotype in pSjS. The same authors also suggested that
there are three different subgroups of patients with pSjS,
based upon interferon activities: type I–predominant
subgroup, type II–predominant subgroup, and mixed type
I/II IFN activity subgroup (21). Therefore, our patients
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with low disease activity might have been in the type I–
predominant subgroup.
Findings of elevated saliva levels of TNF-α and
caspase-1 in the present study and of additional other
cytokines reported in literature such as IL-1β and IFN-γ
may have implications in tailoring local treatment for
patients with pSjS. It may be speculated that systemic
immunosuppressive treatment and achievement of
low disease activity in pSjS may decrease systemic
inflammatory cytokine and enzyme levels more readily
compared to local mucosal microenvironment, which
may be more resistant. The lack of differences in serum
levels of some cytokines and enzymes despite significant
differences in saliva levels, as found in the present
study, might support this speculation. Data from a
prospective double-blind randomized trial demonstrated
that targeting IL-1 by topical application of anakinra is
effective in reducing dry eye disease-related symptoms
and corneal epitheliopathy (22). Likewise, although
systemic anti-TNF treatment is ineffective and rather
may cause exacerbation of Sjögren’s activity (23,24),
local TNF-α inhibition in oral mucosa may be effective,
as suggested by previous experimental data (NOD mice)
(15).
Our study has some limitations. First, the numbers
of patients with pSjS and healthy controls were rather
low. Additionally, immunosuppressive medications were
not stopped before serum and saliva measurements were
made, and all of the pSjS patients had displayed low
disease activity when they were enrolled in this study. This
might have also affected some of our results. On the other
hand, we focused on individual time points to describe
the cytokine profiles of the patients, although fluctuations
in cytokine levels sometimes accompany disease flares or
remissions. We also admit that measuring saliva levels
of certain cytokines by ELISA method may not be as
sensitive as PCR analysis. Finally, for technical reasons,
IL-1β and IL-18 could not be studied in the present study.
In conclusion, despite low disease activity, saliva
caspase-1 and TNF-α levels were found to be significantly
higher in patients with pSjS compared to both healthy
controls and the RA group. In selected cases with increased
local mucosal production of certain proinflammatory
cytokines, it may be an alternative approach to use local
anticytokine treatments, rather than using systemic
anticytokine treatments. Better understanding of the
abnormalities in the cytokine network and their role in the
pathogenesis of pSjS will likely lead to the identification of
the best therapeutic targets for this disease.
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